Peptide Blends · Exact presentation
KLOW · 80 mg Blend
KLOW · 80 mg Blend is a declared multi-component single-vial blend. Evidence for each component does not automatically establish the performance of the combination.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 80 mg presentation, the reference concentration of 26.7 mg/mL mathematically corresponds to 2.996 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 26.7 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.267 mg at this concentration.
Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)
The source chart summarizes “250 mcg–750 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
Reconstitution Steps
For a 80 mg presentation, the reference concentration of 26.7 mg/mL mathematically corresponds to 2.996 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 26.7 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.267 mg at this concentration.
Syringe Math Reference
Linked references apply to KLOW · 80 mg Blend; primary sources, registries, and secondary material are identified separately.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
The proposed mechanism depends on the molecular identity and receptor systems described in the literature. A mechanism alone does not establish clinical efficacy.
Potential Benefits & Side Effects
Identity, purity, sterility, stability, and equivalence to studied products cannot be assumed. Adverse effects and interactions may be incompletely characterized.
Potential Benefits
Evidence may include preclinical findings, exploratory studies, or ongoing human trials. Findings should be interpreted according to study design, population, comparator, and source quality.
Source trail
Scientific references and source discovery
- PeptideDosages — exact KLOW · 80 mg Blend entrysecondary-structure
- PubMed — literature search for KLOWprimary-discovery
- ClinicalTrials.gov — study search for KLOWtrial-registry
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference